TEL AVIV, Israel, December 13, 2010 /PRNewswire-FirstCall/ -- Biological Signal Processing Ltd. ("BSP") (TASE: BSP), which develops and commercializes advanced products for the non invasive, accurate diagnosis of heart diseases, has signed a US non exclusive distribution agreement with Synergistic Medical Network LLC ("SMN"), to distribute and market its products to physicians in clinics and hospitals throughout the United States. BSP's innovative products are based on its proprietary, patented HyperQTM technology which offers first line diagnostics of unmatched performance for the detection of Ischemic Heart Disease (IHD).
"We believe that SMN, with its proven sales track record in the US, is optimally positioned to commercialize our revolutionary products," said Nissim Greisas, CEO of BSP. Mr. Greisas further added: "In an atmosphere of increasing concerns over patient exposure to radiation and recent cutbacks on the payment for costly cardiac imaging modalities, our products provide a novel - low cost, radiation free and accurate IHD diagnostic option, ripe for wide implementation in the US healthcare system."
Tom Newman, Managing Partner of Synergistic Medical Network, LLC (SMN), added, "SMN is excited to now offer the BSP Hyper-Q technology along with our robust family of advanced diagnostic products for the cardiology market. We believe BSP's advanced ischemia detection technology (Hyper-QTM) is another example of our commitment to the Cardiology community channeling added value through innovative leading edge technologies."
The groundbreaking HyperQ(TM) technology utilizes advanced signal processing techniques for extracting and analyzing valuable clinical information from high-resolution ECG signals, providing a novel diagnostic tool with superior accuracy, compared to conventional stress ECG analysis. To date, over 15,000 patients have been tested using HyperQ(TM) systems, in routine use and in clinical studies, with outstanding results.
BSP's product line includes the HyperQTM EX-300, a second generation hybrid system which offers all the functionalities available in first tier Stress ECG machines coupled with the unique HyperQ(TM) analysis. The company also offers the HyperQTM AD-100, an add-on system with the HyperQ technology which is incorporated in parallel to existing standard stress ECG systems, catering to the vast installed base of physicians wishing to benefit from the clinical advantages of the technology without the need to replace their existing installed Stress ECG system.
About Biological Signal Processing Ltd.
Founded in 2000, BSP is dedicated to providing novel, risk free and highly reliable solutions for the diagnosis and monitoring of cardiovascular disease. BSP's proprietary HyperQ(TM) technology is implemented in cardiac systems that offer accurate, low-cost and risk free cardiac monitoring and allows, for the first time, an effective diagnosis of ischemic heart disease in broad populations. BSP shares are traded on the Tel Aviv Stock Exchange since 2006 (TASE: BSP). The company's offices are located in Tel Aviv, Israel and Boston, MA, USA.
About Synergistic Medical Network, LLC
Synergistic Medical Network, LLC, headquartered in California is comprised of a network of over 120 independent representatives covering all 50 states in the US. The company's leadership team has decades of compounded experience in the sales of advanced medical equipment in the US. The company enjoys ongoing relations with thousands of US physicians in a variety of fields, among them the prime audience for BSP's products, i.e. cardiologists with expertise in the non-invasive diagnosis of ischemic heart disease.
Company contacts: Biological Signal Processing Nissim Greisas CEO, BSP email@example.com Tel: +972-3-647-4840 Synergistic Medical Network Frank Luketich Co-Director of Business Development and Hospital Sales, SMN firstname.lastname@example.org
SOURCE BSP - Biological Signal Processing Ltd